A statistical method for estimating the no-observed-adverse-event-level

Research output: Working paper/Preprint › Preprint

Authors

  • Ludwig A. Hothorn

Research Organisations

View graph of relations

Details

Original languageEnglish
Publication statusE-pub ahead of print - 2 Jan 2021

Abstract

In toxicological risk assessment the benchmark dose (BMD) is recommended instead of the no-observed-adverse effect-level (NOAEL). Still a simple test procedure to estimate NOAEL is proposed here, explaining its advantages and disadvantages. Versatile applicability is illustrated using four different data examples of selected in vivo toxicity bioassays.

Keywords

    stat.AP

Cite this

A statistical method for estimating the no-observed-adverse-event-level. / Hothorn, Ludwig A.
2021.

Research output: Working paper/Preprint › Preprint

Download
@techreport{be25acf6b4b54823bf436ab2c1ab321b,
title = "A statistical method for estimating the no-observed-adverse-event-level",
abstract = " In toxicological risk assessment the benchmark dose (BMD) is recommended instead of the no-observed-adverse effect-level (NOAEL). Still a simple test procedure to estimate NOAEL is proposed here, explaining its advantages and disadvantages. Versatile applicability is illustrated using four different data examples of selected in vivo toxicity bioassays. ",
keywords = "stat.AP",
author = "Hothorn, {Ludwig A.}",
note = "4 data examples, with raw data and R-code",
year = "2021",
month = jan,
day = "2",
language = "English",
type = "WorkingPaper",

}

Download

TY - UNPB

T1 - A statistical method for estimating the no-observed-adverse-event-level

AU - Hothorn, Ludwig A.

N1 - 4 data examples, with raw data and R-code

PY - 2021/1/2

Y1 - 2021/1/2

N2 - In toxicological risk assessment the benchmark dose (BMD) is recommended instead of the no-observed-adverse effect-level (NOAEL). Still a simple test procedure to estimate NOAEL is proposed here, explaining its advantages and disadvantages. Versatile applicability is illustrated using four different data examples of selected in vivo toxicity bioassays.

AB - In toxicological risk assessment the benchmark dose (BMD) is recommended instead of the no-observed-adverse effect-level (NOAEL). Still a simple test procedure to estimate NOAEL is proposed here, explaining its advantages and disadvantages. Versatile applicability is illustrated using four different data examples of selected in vivo toxicity bioassays.

KW - stat.AP

M3 - Preprint

BT - A statistical method for estimating the no-observed-adverse-event-level

ER -